Amarin Corp Plc (AMRN)

[Whalatane]

Re

You can reverse split this 1 for 10 and I guarantee the stock is sub $1.00 in 6 months

I'll take that bet ( against U ) . Co has to much cash on hand especially if it can operate breakeven ...for it to lose 80% of its value after a R/S in 6 mths .

By the way ...all a CAD patient like moi needs is Leqvivo ( see previous post ) and Vascepa . Difference is that NVS is funding extra trials to show / confirm Leqvio's risk reduction ..and AMRN isn't

Completed major Leqvio trials to date

Below is a list of key clinical trials conducted for Leqvio (inclisiran), a small interfering RNA (siRNA) therapy used to lower LDL cholesterol:
Phase III Trials
ORION-9:
Participants: 482 patients with heterozygous familial hypercholesterolemia (HeFH).
Results: Reduced LDL-C by 48% compared to placebo at 17 months.
Design: Double-blind, placebo-controlled trial conducted across eight countries1.
ORION-10:
Participants: 1,561 patients with atherosclerotic cardiovascular disease (ASCVD).
Results: LDL-C reduction of 52% compared to placebo at 17 months.
Location: Conducted at 145 sites in the US1.
ORION-11:
Participants: 1,617 patients with ASCVD or ASCVD risk equivalents.
Results: LDL-C reduction of 50% compared to placebo at 17 months.
Location: Conducted across seven countries1.
V-MONO:
Participants: 350 patients at low or moderate ASCVD risk.
Results: Clinically meaningful LDL-C reduction compared to ezetimibe and placebo at day 150.
Design: Randomized, double-blind trial25.
Open-Label Extension Studies
ORION-3:
Extension of ORION-1 trial with 233 participants over four years.
Results: Maintained LDL-C reduction of ~47.5% at Day 210 and ~44.2% over four years with twice-yearly dosing1.
ORION-8:
Largest trial to date, with over 8,500 patient-years of exposure.
Results: Sustained LDL-C reduction (~50%) and consistent safety profile over six years4.

Kiwi